These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7517175)

  • 1. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
    Garver DL; Bissette G; Yao JK; Nemeroff CB
    Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
    van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
    Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
    Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL
    Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia.
    Wieselgren IM; Lindström LH
    Psychiatry Res; 1998 Nov; 81(2):101-10. PubMed ID: 9858027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships.
    van Kammen DP; Peters J; Yao J; Neylan T; Beuger M; Pontius E; O'Connor DT
    Schizophr Res; 1991 Dec; 6(1):31-9. PubMed ID: 1723893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of electroconvulsive therapy on CSF amine metabolites in schizophrenic patients.
    Cooper SJ; Leahey W; Green DF; King DJ
    Br J Psychiatry; 1988 Jan; 152():59-63. PubMed ID: 2458796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history.
    Lindström LH
    Psychiatry Res; 1985 Apr; 14(4):265-73. PubMed ID: 2410940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced CSF neurotensin concentration in drug-free schizophrenic patients.
    Lindström LH; Widerlöv E; Bisette G; Nemeroff C
    Schizophr Res; 1988; 1(1):55-9. PubMed ID: 3154507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome.
    Nemeroff CB; Bissette G; Widerlov E; Beckmann H; Gerner R; Manberg PJ; Lindstrom L; Prange AJ; Gattaz WF
    J Neuropsychiatry Clin Neurosci; 1989; 1(1):16-20. PubMed ID: 2577718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF monoamine metabolites in schizophrenic patients.
    Gattaz WF; Waldmeier P; Beckmann H
    Acta Psychiatr Scand; 1982 Nov; 66(5):350-60. PubMed ID: 6184954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide.
    Roy A; Ninan P; Mazonson A; Pickar D; Van Kammen D; Linnoila M; Paul SM
    Psychol Med; 1985 May; 15(2):335-40. PubMed ID: 2410941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melperone in the treatment of schizophrenia.
    Bjerkenstedt L
    Acta Psychiatr Scand Suppl; 1989; 352():35-9. PubMed ID: 2479227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.
    Sedvall G
    Prog Biochem Pharmacol; 1980; 16():133-40. PubMed ID: 6160594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ; Leahey W; Liddle J; King DJ
    Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment.
    Widerlöv E; Lindström LH; Besev G; Manberg PJ; Nemeroff CB; Breese GR; Kizer JS; Prange AJ
    Am J Psychiatry; 1982 Sep; 139(9):1122-6. PubMed ID: 6126127
    [No Abstract]   [Full Text] [Related]  

  • 18. The dopamine-serotonin relationship in clozapine response.
    Szymanski S; Lieberman J; Pollack S; Munne R; Safferman A; Kane J; Kronig M; Cooper T
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S85-9. PubMed ID: 7530378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients.
    Sedvall GC; Wode-Helgodt B
    Arch Gen Psychiatry; 1980 Oct; 37(10):1113-6. PubMed ID: 6158928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
    Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ
    Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.